CSIMarket Company Name, Ticker, Industry, else..
 
Meiragtx Holdings Plc  (MGTX)
Other Ticker:  
 
 
Price: $4.6400 $0.39 9.176%
Day's High: $4.64 Week Perf: 11.81 %
Day's Low: $ 4.23 30 Day Perf: 9.18 %
Volume (M): 328 52 Wk High: $ 7.60
Volume (M$): $ 1,521 52 Wk Avg: $5.13
Open: $4.24 52 Wk Low: $3.49



 Market Capitalization (Millions $) 299
 Shares Outstanding (Millions) 64
 Employees 106
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -93
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 10

Meiragtx Holdings Plc
MeiraGTx Holdings Plc is a clinical-stage gene therapy company that focuses on the development of transformative treatments for various genetic diseases. The company utilizes its proprietary technology platform to create gene therapies that address the underlying causes of these diseases. MeiraGTx is dedicated to advancing the field of gene therapy through its innovative research, partnerships, and collaborations. The company has a diverse pipeline of programs targeting a range of genetic disorders, including ocular diseases, neurodegenerative disorders, and rare diseases. MeiraGTx aims to provide patients with long-term, durable treatments that can significantly improve their quality of life.


   Company Address: 450 East 29th Street New York 10016 NY
   Company Phone Number: 860-7985   Stock Exchange / Ticker: NASDAQ MGTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Hope on the Horizon: Positive Data from Phase 1 AQUAx Study Brings Promising Results for Patients with Radiation-Induced Xerostomia,

Published Mon, Aug 12 2024 11:06 AM UTC

Positive Results from Phase 1 AQUAx Study Bring Hope for Patients with Radiation-Induced Xerostomia
Radiation therapy is a common treatment for head and neck cancers, but it often comes with side effects such as radiation-induced xerostomia (RIX), also known as dry mouth. This condition can significantly impact a patient's quality of life, making it difficult to speak, e...
Meiragtx Holdings Plc

Meiragtx Holdings Plc Faces Tough Challenges in Recent Fiscal Quarter



MeiraGTx Holdings Plc, a leading biopharmaceutical company, reported its financial results for the January to March 31, 2024 interval, which revealed a loss in earnings per share but positive advancements in its clinical trials and debt management. Despite facing some setbacks, the company's recent achievements and improvements signal potential growth and are expected to have a positive impact on its future prospects.
Positive Clinical Trial Data:
One major highlight for MeiraGTx is the positive data presented from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) at the American Academy of Oral Medicine 2024 annual meeting. The encouraging results indicate progress in developing an effective treatment for this debilitating condition which affects salivary gland function, potentially positioning the company as a frontrunner in addressing RIX. This achievement demonstrates MeiraGTx's commitment to developing innovative treatment options.
Meiragtx Holdings Plc

Meiragtx Holdings Plc Surges to Profitability in Recent Financial Time-frame

Meiragtx Holdings Plc, a prominent biotechnology and pharmaceutical company, has shown tremendous improvement in its financial performance in the most recent fiscal period. The company's Income per Share has turned around from a loss of $0.58 per share in the previous year to a profit of $0.26 per share. This significant improvement indicates a positive shift in the company's profitability.
Furthermore, in the prior financial reporting period, Meiragtx Holdings Plc experienced a loss of $0.74 per share. However, they have successfully achieved a net income of $20.215 million in the financial timeframe ending December 31, 2023, compared to a net loss of $-27.313 million in the corresponding financial reporting period a year ago. This remarkable improvement in net income demonstrates the company's ability to generate positive financial results.
Financing Agreement

MeiraGTx Receives $50 Million Milestone for XLRP Treatment and Improves Total Debt to Equity Ratio

Published Tue, Feb 13 2024 1:01 PM UTC


In a significant development for MeiraGTx, the company is set to receive a $50 million milestone payment after initiating the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec), formerly known as AAV-RPGR, for the treatment of X-linked retinitis pigmentosa (XLRP). This milestone payment from Janssen Pharmaceuticals reflects p...
Financing Agreement

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million, Fueling Hope for X-linked Retinitis Pigmentosa Patients

Published Thu, Dec 21 2023 12:00 PM UTC

MeiraGTx Announces $415 Million Asset Purchase Agreement for X-linked Retinitis Pigmentosa Treatment
MeiraGTx Holdings Plc, a leading gene therapy company, has recently entered into an Asset Purchase Agreement related to botaretigene sparoparvovec (known as bota-vec, formerly AAV-RPGR). This agreement aims to further develop and commercialize bota-vec for the treatment o...






Meiragtx Holdings Plc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com